DOCSLIB.ORG

Sex Without Disclosure of Positive HIV Serostatus in a US Probability Sample of Persons Receiving Medical Care for HIV Infection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sex Without Disclosure of Positive HIV Serostatus in a US Probability Sample of Persons Receiving Medical Care for HIV Infection CHILD POLICY This PDF document was made available from www.rand.org as a public CIVIL JUSTICE service of the RAND Corporation. EDUCATION ENERGY AND ENVIRONMENT Jump down to document HEALTH AND HEALTH CARE 6 INTERNATIONAL AFFAIRS NATIONAL SECURITY The RAND Corporation is a nonprofit research POPULATION AND AGING PUBLIC SAFETY organization providing objective analysis and effective SCIENCE AND TECHNOLOGY solutions that address the challenges facing the public SUBSTANCE ABUSE and private sectors around the world. TERRORISM AND HOMELAND SECURITY TRANSPORTATION AND INFRASTRUCTURE Support RAND Browse Books & Publications Make a charitable contribution For More Information Visit RAND at www.rand.org Explore RAND Health View document details Limited Electronic Distribution Rights This document and trademark(s) contained herein are protected by law as indicated in a notice appearing later in this work. This electronic representation of RAND intellectual property is provided for non-commercial use only. Permission is required from RAND to reproduce, or reuse in another form, any of our research documents for commercial use. RESEARCH AND PRACTICE Sex Without Disclosure of Positive HIV Serostatus in a US Probability Sample of Persons Receiving Medical Care for HIV Infection | Daniel H. Ciccarone, MD, MPH, David E. Kanouse, PhD, Rebecca L. Collins, PhD, Angela Miu, MS, James L. Chen, MPH, Sally C. Morton, PhD, and Ron Stall, PhD It is difficult to identify a more charged Objectives. We estimated the proportion of HIV-positive adults who have any sexual issue in AIDS prevention than that of contact without disclosure and the proportion of their sexual partnerships that involve nondisclosure of positive HIV status to sex- unprotected sex without disclosure. ual partners. Seropositive individuals who Methods. We drew participants from the HIV Cost and Services Utilization Study do not disclose their status to sexual part- (n=1421). Interviews assessed disclosure and sexual activities with up to 5 recent ners are often portrayed as dangerous pari- partners. ahs.1 As of 1999, 31 states had statutes Results. Overall, 42% of the gay or bisexual men, 19% of the heterosexual men, and making sexual contact without disclosure a 17% of all the women reported any sex without disclosure, predominately within nonex- criminal offense.2 Public health researchers, clusive partnerships (P<.001). Across all groups, 13% of serodiscordant partnerships involved unprotected anal or vaginal sex without disclosure, with no significant differ- responding to data reporting sexual contact ence between groups. without disclosure by HIV-positive persons, Conclusions. Risky sex without disclosure of serostatus is not uncommon among have called for interventions to promote in- people with HIV. (Am J Public Health. 2003;93:949–954) creased sexual responsibility and to in- crease rates of consistent safer sex among HIV-positive persons.3,4 als’ behavior varies according to their part- METHODS Public discourse on this topic is heavily ners’ HIV status and condom use. influenced by a few well-publicized cases in We report data from the Risk and Pre- Sample Description which individuals who knew they were HIV vention Study subset of the nationally rep- Respondents were participants in the positive reportedly infected a series of un- resentative probability sample of the HIV HCSUS, a national probability sample of suspecting partners. The public health sig- Cost and Services Utilization Study 2864 persons aged 18 years or older with nificance of nondisclosure, however, de- (HCSUS). We describe (1) the extent to known HIV infection who made at least 1 pends on both its prevalence and the which Americans in treatment for HIV visit to a nonmilitary, nonprison medical riskiness of the behaviors that occur with- have sex without disclosure, (2) the extent provider other than an emergency depart- out disclosure—that is, the extent to which to which this population has unprotected sex ment in the contiguous United States during sex without disclosure is unprotected sex without disclosure, and (3) the extent to the first 2 months of 1996. Full details of the between serodiscordant partners. Previous which unprotected sex without disclosure HCSUS design are available elsewhere.16 ,17 studies show that not disclosing positive occurs within serodiscordant sexual part- The Risk and Prevention Study subset used HIV serostatus to at least some sexual part- nerships. To the best of our knowledge, this for our study consisted of 1421 HCSUS par- ners is common,5–7 that HIV-positive per- is the first study to report data on the ex- ticipants. Eligible members of the HCSUS sons are more likely to disclose their status tent of sex without disclosure from a proba- sample were those who were interviewed in to steady partners than to nonsteady part- bility sample of HIV-positive adults in the English at the HCSUS baseline interview, ners,8–10 and that unprotected sex without United States and the first to provide com- whose sex was unambiguous on the basis of disclosure occurs within both types of part- parative data across risk groups. Because HCSUS data, and who participated in the sec- nerships.5,9 Much of the previous research data were collected on partnerships, we can ond follow-up HCSUS interview, conducted on this topic focused on specific subpopula- examine disclosure at both the dyad and in- from August 1997 through January 1998 tions, such as gay and bisexual men,9,11 dividual levels. We hope that this analysis (n=2205). We drew 1794 individuals from men in general,12 or women.7,13,14 Studies will help inform policy and intervention de- this group, sampling randomly after stratifying that included both sexes or multiple risk bates on the best ways to encourage disclo- by primary HCSUS sampling unit, type of groups8,10,15 generally did not use suffi- sure among HIV-positive persons and safer health care provider, age, ethnicity, and self- ciently large sample sizes to support de- sex practices among the broad range of described sexual orientation. We randomly tailed group comparisons. Nor did previous Americans infected with HIV or at risk of sampled one third of eligible White gay men studies examine whether and how individu- infection. aged 40 years, 44% of eligible White gay June 2003, Vol 93, No. 6 | American Journal of Public Health Ciccarone et al. | Peer Reviewed | Research and Practice | 949 RESEARCH AND PRACTICE men aged 39 years and younger, and 100% of engaging in oral, anal, and vaginal sex; to examine the prevalence of abstinence, sex of all other groups. We conducted interviews consistency of condom use with each activity; only with disclosure, any sex without disclo- from September through December 1998. disclosure; and timing of sexual activity rela- sure, and any unprotected anal or vaginal sex The completion rate was 79%, and the re- tive to disclosure. without disclosure by risk group. To adjust sponse rate after adjustment for known mor- standard errors and statistical tests for the dif- Measures tality was 84%. ferential weighting and complex sample de- Sexually active respondents were those re- The Risk and Prevention Study subsample sign, we used linearization methods18 , 2 0 avail- porting any oral, anal, or vaginal sex in the was weighted to represent a target population able in the statistical package Stata (Stata preceding 6 months; all others were consid- of 197063 HIV-positive adults receiving Corp, College Station, Tex). ered abstinent. Aggregating across partners, medical care in the 48 contiguous states of Analyses at the partnership level focused we classified each active respondent into 1 of the United States in 1996 and surviving until on 1273 serodiscordant partnerships, exam- 2 mutually exclusive categories reflecting be- 19 9 8. The analytic weights take into account ining the prevalence of unprotected anal havior in the past 6 months: (1) had sex only differential selection probabilities, nonre- and vaginal sex within these partnerships. after disclosure, and (2) had any sex without sponse, multiplicity, and attrition.18 Men who Results for the multiple partners of a re- disclosure. Respondents who refused to an- identified themselves as “gay,” “bisexual,” or spondent might be correlated. In a sensitiv- swer whether there had been any sex before “heterosexual” and all women were included ity analysis, we adjusted for this design ef- disclosure were classified as missing data in the analysis reported in this article. Men fect by treating each individual and his or (n=7); those who said they didn’t know or who specified “other” or who did not report her associated partners as a primary sam- who were otherwise missing data were their sexual orientation were excluded pling unit and by using the same analytic treated as having had sex only after disclo- (n=24). Tables show proportions weighted to weights. Because the sensitivity analysis sure (n=45). represent the population, as well as un- yielded the same conclusions as our original Within partnerships, we first combined weighted sample sizes. analysis, which did not account for the cor- the “sex without disclosure” variable with relation among partners, and because the consistency of condom use (“always” vs any Survey Instrument and Procedures sensitivity analysis reduced our statistical other response) for anal and for vaginal sex The Risk and Prevention Study covered power owing to the design effect, we pres- and then aggregated across partners to cre- sexual activities, attitudes, and beliefs
Load more

Recommended publications
  • What You Should Know About HIV and AIDS
    WHAT YOU SHOULD KNOW ABOUT HIV & AIDS WHAT IS AIDS? AIDS is the Acquired Immune Deficiency Syndrome – a serious illness that makes the body unable to fight infection. A person with AIDS is susceptible to certain infections and cancers. When a person with AIDS cannot fight off infections, this person becomes ill. These infections can eventually kill a person with AIDS. WHAT CAUSES AIDS? The human immunodeficiency virus (HIV) causes AIDS. Early diagnosis of HIV infection is important! If you have been told that you have HIV, you should get prompt medical treatment. In many cases, early treatment can enhance a person’s ability to remain healthy as long as possible. Free or reduced cost anonymous and confidential testing with counseling is available at every local health department in Kentucky. After being infected with HIV, it takes between two weeks to three months before the test can detect antibodies to the virus. HOW IS THE HIV VIRUS SPREAD? Sexual contact (oral, anal, or vaginal intercourse) with an infected person when blood, pre-ejaculation fluid, semen, rectal fluids or cervical/vaginal secretions are exchanged. Sharing syringes, needles, cotton, cookers and other drug injecting equipment with someone who is infected. Receiving contaminated blood or blood products (very unlikely now because blood used in transfusions has been tested for HIV antibodies since March 1985). An infected mother passing HIV to her unborn child before or during childbirth, and through breast feeding. Receipt of transplant, tissue/organs, or artificial insemination from an infected donor. Needle stick or other sharps injury in a health care setting involving an infected person.
    [Show full text]
  • International Guidelines on HIV/AIDS and Human Rights 2006 Consolidated Version
    International Guidelines on HIV/AIDS and Human Rights 2006 Consolidated Version Second International Consultation on HIV/AIDS and Human Rights Geneva, 23-25 September 1996 Third International Consultation on HIV/AIDS and Human Rights Geneva, 25-26 July 2002 Organized jointly by the Office of the United Nations High Commissioner for Human Rights and the Joint United Nations Programme on HIV/AIDS OFFICE OF THE UNITED NATIONS HIGH COMMISSIONER FOR HUMAN RIGHTS Material contained in this publication may be freely quoted or reprinted, provided credit is given and a copy containing the reprinted material is sent to the Office of the United Nations High Commissioner for Human Rights, CH-1211 Geneva 10, and to UNAIDS, CH-1211 Geneva 27, Switzerland. The designations employed and the presentation of the material in this publication do not imply expression of any opinion whatsoever on the part of the Secretariat of the United Nations or UNAIDS concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Published jointly by the Office of the United Nations High Commissioner for Human Rights and the Joint United Nations Programme on HIV/AIDS. HR/PUB/06/9 UN PUBLICATION Sales No. E.06.XIV.4 ISBN 92-1-154168-9 © Joint United Nations Programme on HIV/AIDS (UNAIDS) 2006. All rights reserved. Publications produced by UNAIDS can be obtained from the UNAIDS Information Centre. Requests for permission to translate UNAIDS publications—whether for sale or for noncommercial distribution—should also be addressed to the Information Centre at the address below, or by fax, at +41 22 791 4187, or e-mail: [email protected].
    [Show full text]
  • CURRICULUM VITAE Updated on Jan 24, 2020
    T. Davtyan, Armenia CURRICULUM VITAE Updated on Jan 24, 2020 Surname Davtyan First name(s) Tigran Affiliation and official address Rhea Pharmaceutical Armenia LLC Armenia, 0084, Yerevan Gusan Sherami St., 2 Building (Malatia-Sebastia adm. district) Republic of Armenia Tel.: (+374-) 91 400994, 98-55-96-29 E-mail: [email protected] [email protected] Present Positions: Professor, Chief Scientist Rhea Pharmaceutical Armenia LLC Home address: Michurin str. 5, 23, 375041, Yerevan, Republic of Armenia. Tel: +374 10 55-96-29 Date and Place of birth: 1 December, 1966, Yerevan, Armenia Nationality: Armenian Citizenship: Republic of Armenia Passport ARM, AH0248176, 24 OCT 2006, 009 ID № 1112660259 Marital status: Married, has 2 children, 3 grandchild Education (degrees, dates, universities) 2016 Professor. Field: Biology 2003 Doctor of Biological Sciences (ScD). Field: Molecular Biology 1993 Candidate of Biological Sciences (Ph.D); Field :Genetics and Immunology 1989-1992 Ph.D. student, Laboratory of Genetic Mechanisms of Cell Malignization And Differentiation, Institute of Cytology, St. Petersburg, Russia. 1983-1988 Yerevan State Medical University, Faculty of Pharmacy Specialization (specify) Drug Design and quality control, HIV/AIDS and clinical immunology; Viral infections; immunity and stress resistance; Molecular mechanisms and Genetic regulation of innate immune response; Autoinflammation; 1 T. Davtyan, Armenia Career/Employment (employers, positions and dates) 2011- 2019 Director of Analytical Laboratory of Scientific Centre of Drug and Medical Thechnology Experttise JSC 1999 - 2011 Head of HIV-Clinical Trail Laboratory of the ARMENICUM Research Center, Yerevan, Rep. of Armenia. 1998 - 2006 Consultant on Science, Laboratory of Immunology, The Second Clinical Hospital of the Yerevan State Medical University, Rep.
    [Show full text]
  • HIV an Illusion Toxic Shock
    SCIENTIFIC CORRESPONDENCE generated from a linear model could be a and Ho's] data is remarkable", note that vmons per day is not defined or function of both the baseline CD4 level Loveday et al. 8 report the use of a PCR­ addressed, nor can it be! No one else has and viral loads. Further studies with larg­ based assay and find only 200 HIV "virion access to either the unapproved drugs or er sample sizes are needed to resolve RNAs" per ml of serum of AIDS patients the branch PCR technology! What is the these discrepancies. - 1,000 times less than Ho and Wei. So benchmark rate for the turnover of CD4 Shenghan Lai, J. Bryan Page, Hong Lai much for the "remarkable concordance". cells in the general population? Departments of Medicine, Peter Duesberg To counter the 42 case studies of Wei et Psychiatry and Epidemiology, Department of Molecular and Cellular al. 1 and Ho et al.2, we at HEAL (Health University of Miami School of Medicine, Biology, University of California, Education AIDS Liason) can provide at Miami, Florida 33136, USA Berkeley, California 94720, USA least 42 people who are western-blot-posi­ Harvey Bialy tive for 'HIV', have low T4 cells, who are Bio/Technology, New York, not using orthodox procedures, and have HIV an illusion New York 10010, USA been healthy for years! On the other 1. Maddox, J. Nature 373, 189 (1995). hand, we can also provide you with hun­ SIR - In an editorial' in the 19 January 2. Ho, D.D. et al. Nature 373, 123-126 (1995).
    [Show full text]
  • A History of the Hiv/Aids Epidemic with Emphasis on Africa *
    UN/POP/MORT/2003/2 5 September 2003 ENGLISH ONLY WORKSHOP ON HIV/AIDS AND ADULT MORTALITY IN DEVELOPING COUNTRIES Population Division Department of Economic and Social Affairs United Nations Secretariat New York, 8-13 September 2003 A HISTORY OF THE HIV/AIDS EPIDEMIC WITH EMPHASIS ON AFRICA * UNAIDS and WHO ** * This document was reproduced without formal editing. ** UNAIDS, Geneva and WHO, Geneva. The views expressed in the paper do not imply the expression of any opinion on the part of the United Nations Secretariat. Quality and Coverage of HIV Sentinel Surveillance With a brief History of the HIV/AIDS Epidemic Workshop on HIV/AIDS and Adult Mortality in Developing Countries New York, 8-13 September 2003 2 1 History of the HIV/AIDS epidemic with emphasis on Africa In 1981, a new syndrome, the acquired immune deficiency syndrome (AIDS), was first recognized among homosexual men in the United States. By 1983, the etiological agent, the human immunodeficiency virus (HIV), had been identified. By the mid-1980’s, it became clear that the virus had spread, largely unnoticed, throughout most of the world. The HIV/AIDS pandemic consists of many separate epidemics. Each epidemic has its own distinct origin, in terms of geography and specific populations affected, and involve different types and frequencies of risk behaviors and practices, for example, unprotected sex with multiple partners or sharing drug injection equipment. Countries can be divided into three states: generalized, concentrated and low. Low Principle: Although HIV infection may have existed for many years, it has never spread to significant levels in any sub-population.
    [Show full text]
  • Duesberg and Critics Agree: Hemophilia Is the Best Test
    SPECIAL NEWS REPORT 1 REVIEWING THE DATA–I the Multicenter Hemophilia Cohort Study 66 2 (MHCS) sponsored by the National Cancer 65 3 Institute (NCI), follows 2000 hemophiliacs 64 4 Duesberg and Critics Agree: at 16 centers in the United States and West- 63 5 ern Europe. In 1989, the New England Journal 62 6 Hemophilia Is the Best Test of Medicine published a study from the 61 7 MHCS comparing 242 HIV-infected hemo- 60 8 philiacs who received high, medium, or low 59 9 Peter Duesberg and his critics in the com- addition, some researchers contacted by Sci- doses of factor VIII. If exposure to contami- 58 10 munity of AIDS researchers disagree vio- ence say Duesberg has drawn incorrect con- nants in factor VIII were the cause of the 57 11 lently about the cause of AIDS. But they clusions from their work. immune suppression seen in AIDS, it would 56 12 agree on one thing: Hemophiliacs provide a In making his argument that hemophili- be expected that those who received higher 55 13 good test of the hypothesis that HIV causes acs suffer from AIDS independent of HIV, doses of the factor would be more likely to 54 14 AIDS. Hemophiliacs offer a unique window Duesberg cites 16 studies showing that HIV- develop AIDS, says NCI’s James Goedert, 53 15 on the effects of HIV infection because there negative hemophiliacs have abnormal ratios the principal investigator of MHCS. But the 52 16 are solid data comparing those who have of two types of critical immune-system cells: study, says Goedert, found no association 51 17 tested positive for antibodies to HIV—and CD4 and CD8.
    [Show full text]
  • AIDS Denialism Beliefs Among People Living with HIV/AIDS
    J Behav Med (2010) 33:432–440 DOI 10.1007/s10865-010-9275-7 ‘‘There is no proof that HIV causes AIDS’’: AIDS denialism beliefs among people living with HIV/AIDS Seth C. Kalichman • Lisa Eaton • Chauncey Cherry Received: February 1, 2010 / Accepted: June 11, 2010 / Published online: June 23, 2010 Ó Springer Science+Business Media, LLC 2010 Abstract AIDS denialists offer false hope to people liv- example, claim that Nazi Germany did not systematically ing with HIV/AIDS by claiming that HIV is harmless and kill 6 million Jews (Shermer and Grobman 2000) and that AIDS can be cured with natural remedies. The current Global Warming Deniers believe that climatology is a study examined the prevalence of AIDS denialism beliefs flawed science with no proof of greenhouse gases changing and their association to health-related outcomes among the atmosphere (Lawler 2002). Among the most vocal people living with HIV/AIDS. Confidential surveys and anti-science denial movements is AIDS Denialism, an out- unannounced pill counts were collected from a conve- growth of the radical views of University of California nience sample of 266 men and 77 women living with HIV/ biologist Duesberg and his associates (1992, 1994; Duesberg AIDS that was predominantly middle-aged and African and Bialy 1995; Duesberg and Rasnick 1998). Duesberg American. One in five participants stated that there is no claims that HIV and all other retroviruses are harmless and proof that HIV causes AIDS and that HIV treatments do that AIDS is actually caused by illicit drug abuse, poverty, more harm than good. AIDS denialism beliefs were more and antiretroviral medications (Duesberg et al.
    [Show full text]
  • The Natural History of HIV-1 and HIV-2 Infections in Adults in Africa: a Literature Review Shabbar Jaffar,1, 2 Alison D
    The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review Shabbar Jaffar,1, 2 Alison D. Grant,2 Jimmy Whitworth,2, 3 Peter G. Smith,1, 2 & Hilton Whittle4 Abstract About 30 million people in Africa are estimated to be living with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), yet data about the natural history of infection on the continent are sparse. We reviewed the literature on the natural history of HIV-1 and HIV-2 infections among African adults. Only one study, conducted in rural Uganda, has reported on survival from the time of HIV-1 seroconversion: the median was 9.8 years, which is similar to that reported in developed countries in the early stages of the epidemic and consistent with the findings from the follow-up of individuals identified by serological testing during community-based prevalence studies from Africa. Progression to symptomatic disease was faster in Uganda than in developed countries, due largely to the high background level of morbidity. Various studies suggest that people infected with HIV-2 survive longer and the course of the disease is possibly more variable than in people infected with HIV-1. However no studies have investigated survival from time of seroconversion among people infected with HIV-2. The majority of patients in hospital in Africa with either HIV-1 or HIV-2 have the clinical features of AIDS just before they die, and many are severely immunosuppressed. This is similar to the situation in developed countries before the introduction of highly active antiretroviral therapy (HAART).
    [Show full text]
  • Overview of HIV/AIDS Globally
    Natalia A. Feduschak, a Kaiser International Fellow and a freelance journalist, wrote and delivered the following lectures about HIV/AIDS to journalism students at the Kyiv National Taras Shevchenko University and Kyiv International University between April 2005 and November 2006. The lectures are based on her own research and interviews conducted in Ukraine and Europe, through resources provided by the Kaiser Family Foundation, Transatlantic Partners Against AIDS, numerous Ukrainian non-profit groups and the experiences of people living with HIV/AIDS. Lecture 1: Overview of HIV/AIDS Globally HIV/AIDS is one of the most important social, political and health issues affecting Ukraine today. Despite its importance, however, the subject remains far from society’s consciousness and is still not adequately covered in the Ukrainian media. The stories that do appear are often dry, consisting of statistics that mean little to the reader, or do not approach HIV/AIDS in a way that makes the issue pertinent to people’s lives. The purpose of this course is two-fold: to convince young journalists that HIV/AIDS merits consistent and in-depth reporting, and to give them the tools to do so. Over the next five weeks, we will look at the HIV/AIDS situation globally, regionally, and in Ukraine. In addition, we will discuss important related issues, such as HIV/AIDS as a national security issue, access to medication and the link between TB, alcoholism and HIV/AIDS. Finally, we will discuss source development and the ethics and professionalism of reporting on HIV/AIDS. Our reading materials will be varied, consisting of a handbook on reporting about HIV/AIDS, which was written by the Kaiser Family Foundation, a private U.S.
    [Show full text]
  • Guidelines for the Use of Antiretroviral Agents in Adults and Adolescent Living With
    Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC) How to Cite the Adult and Adolescent Guidelines: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/ AdultandAdolescentGL.pdf. Accessed [insert date] [insert page number, table number, etc. if applicable] It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is available on the HIVinfo Web site (http://hivinfo.nih.gov). What’s New in the Guidelines? August 16, 2021 Hepatitis C Virus/HIV Coinfection • Table 18 of this section has been updated to include recommendations regarding concomitant use of fostemsavir or long acting cabotegravir plus rilpivirine with different hepatitis C treatment regimens. June 3, 2021 What to Start • Since the release of the last guidelines, updated data from the Botswana Tsepamo study have shown that the prevalence of neural tube defects (NTD) associated with dolutegravir (DTG) use during conception is much lower than previously reported. Based on these new data, the Panel now recommends that a DTG-based regimen can be prescribed for most people with HIV who are of childbearing potential. Before initiating a DTG-based regimen, clinicians should discuss the risks and benefits of using DTG with persons of childbearing potential, to allow them to make an informed decision.
    [Show full text]
  • HIV Subtype Diversity Worldwide
    REVIEW CURRENT OPINION HIV subtype diversity worldwide Nicholas Bbosaa, Pontiano Kaleebua,b, and Deogratius Ssemwangaa,b Purpose of review To provide a summary of the current data on the global HIV subtype diversity and distribution by region. HIV is one of the most genetically diverse pathogens due to its high-mutation and recombination rates, large population size and rapid replication rate. This rapid evolutionary process has resulted in several HIV subtypes that are heterogeneously globally distributed. Recent findings Subtype A remains the most prevalent strain in parts of East Africa, Russia and former Soviet Union countries; subtype B in Europe, Americas and Oceania; subtype C in Southern Africa and India; CRF01_AE in Asia and CRF02_AG in Western Africa. Recent studies based on near full-length genome sequencing highlighted the growing importance of recombinant variants and subtype C viruses. Summary The dynamic change in HIV subtype distribution presents future challenges for diagnosis, treatment and vaccine design and development. An increase in recombinant viruses suggests that coinfection and superinfection by divergent HIV strains has become more common necessitating continuous surveillance to keep track of the viral diversity. Cheaper near full-length genome sequencing approaches are critical in improving HIV subtype estimations. However, missing subtype data and low sequence sampling levels are still a challenge in some geographical regions. Video abstract http://links.lww.com/COHA/A14. Keywords diversity, HIV, subtype INTRODUCTION global HIV pandemic since its inception, other group As of 2017, there were 36.9 million people living with N, O and P viruses have not been disseminated widely. HIV worldwide with a majority of these infections in Group M viruses are further subdivided into nine sub-Saharan Africa [1].
    [Show full text]
  • 2019 ANNUAL REPORT a Message from the CEO and Chair of the GMHC Board
    THE GMHC DIFFERENCE 2019 ANNUAL REPORT A Message from the CEO and Chair of the GMHC Board Dear GMHC Community: GMHC excels in many ways, ensuring the communities we serve have access to high-quality HIV/AIDS services. Our comprehensive approach is designed to help people living with HIV/AIDS overcome barriers to healthy, productive lives. For nearly four decades, GMHC has been a major partner with the City of New York and the State of New York in fighting to end the AIDS epidemic. In 2019, our contributions helped push new HIV infections to an historic low of 1,772. Our programs reach into communities where the epidemic now concentrates, particularly young Black and Latinx men who have sex with men. The HIV care continuum is a public health model that outlines the stages people with HIV go through from diagnosis to achieving and maintaining viral suppression—the key to positive health outcomes and the virtual elimination of the risk of transmission. We work across nearly every step of the HIV care continuum. Again this year, our impact can be seen in our exceptionally high rates of linkage to care, adherence, and viral suppression rates: 91 percent of people who test HIV positive at GMHC were linked to care; 89 percent were adherent to treatment; and 94 percent were virally suppressed. Our comprehensive model is vital to achieving these outcomes. In particular, our services work to address the barriers such as housing and food insecurity and other social determinants of health that prevent people from accessing and adhering to treatment.
    [Show full text]